Dissecting the immune response of CD4+ T cells in Alzheimer’s disease

Author:

Kostic Milos1ORCID,Zivkovic Nikola2,Cvetanovic Ana3,Basic Jelena4,Stojanovic Ivana4

Affiliation:

1. Department of Immunology, Medical Faculty of Nis , University of Nis , Blvd. dr Zorana Djindjica 81 , Nis , 18000 , Serbia

2. Department of Pathology, Medical Faculty of Nis , University of Nis , Blvd. dr Zorana Djindjica 81 , Nis , 18000 , Serbia

3. Department of Oncology, Medical Faculty of Nis , University of Nis , Blvd. dr Zorana Djindjica 81 , Nis , 18000 , Serbia

4. Department of Biochemistry, Medical Faculty of Nis , University of Nis , Blvd. dr Zorana Djindjica 81 , Nis , 18000 , Serbia

Abstract

Abstract The formation of amyloid-β (Aβ) plaques is a neuropathological hallmark of Alzheimer’s disease (AD), however, these pathological aggregates can also be found in the brains of cognitively unimpaired elderly population. In that context, individual variations in the Aβ-specific immune response could be key factors that determine the level of Aβ-induced neuroinflammation and thus the propensity to develop AD. CD4+ T cells are the cornerstone of the immune response that coordinate the effector functions of both adaptive and innate immunity. However, despite intensive research efforts, the precise role of these cells during AD pathogenesis is still not fully elucidated. Both pathogenic and beneficial effects have been observed in various animal models of AD, as well as in humans with AD. Although this functional duality of CD4+ T cells in AD can be simply attributed to the vast phenotype heterogeneity of this cell lineage, disease stage-specific effect have also been proposed. Therefore, in this review, we summarized the current understanding of the role of CD4+ T cells in the pathophysiology of AD, from the aspect of their antigen specificity, activation, and phenotype characteristics. Such knowledge is of practical importance as it paves the way for immunomodulation as a therapeutic option for AD treatment, given that currently available therapies have not yielded satisfactory results.

Funder

Ministry of Science, Technological Development, and Innovation of the Republic of Serbia

Publisher

Walter de Gruyter GmbH

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3